Home » Authors » Aaron Lorenzo

Articles by Aaron Lorenzo

Aton Ends $48.7M Series A With $13.7M Third Tranche

Jan. 9, 2003

By Aaron Lorenzo

PDL Enters Deal With MedImmune, Spells Out Development Strategy

Jan. 8, 2003

By Aaron Lorenzo

XenoPort, ALZA Form Alliance For Delivery Of Three Products

Jan. 8, 2003

By Aaron Lorenzo

PDL Enters Deal With MedImmune, Spells Out Development Strategy

Jan. 8, 2003

By Aaron Lorenzo

XenoPort, ALZA Form Alliance For Delivery Of Three Products

Jan. 8, 2003

By Aaron Lorenzo

Endo Gains Rights To Pain Drugs Through Deal With SkyePharm

Jan. 6, 2003

By Aaron Lorenzo

Raven Raises $40M To Advance Monoclonal Antibody Programs

Jan. 6, 2003

By Aaron Lorenzo

Endo Gains Rights To Pain Drugs Through Deal With SkyePharm

Jan. 6, 2003

By Aaron Lorenzo

Raven Raises $40M To Advance Monoclonal Antibody Programs

Jan. 6, 2003

By Aaron Lorenzo

Cellegy Enters Deal With PDL For Marketing Of Tostrex Gel

Jan. 3, 2003

By Aaron Lorenzo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 11, 2025.
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...